University of Toledo Medical Center
Welcome,         Profile    Billing    Logout  
 23 Trials 
34 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Skeel, Roland T
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC
Active, not recruiting
2
68
US, RoW
Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®
Effector Therapeutics, Medpace, Inc., ICON plc
Non-small Cell Lung Cancer
10/24
12/24
NCT05001516: Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors

Completed
1
17
US
LM-302
Turning Point Therapeutics, Inc.
Advanced Solid Tumor
01/24
01/24
NCT03819387: A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Completed
1
49
US
NBF-006
Nitto BioPharma, Inc.
Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
11/23
03/24
Dworkin, Lance D
NCT05599815: Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome

Withdrawn
2
5
US
ADX-629
Aldeyra Therapeutics, Inc.
Nephrotic Syndrome
05/23
05/23
Elmer, Lawrence
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
522
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
06/24
06/24
Peters, Mathilde C
NCT02690363: Clinical Performance of Posterior Glass Ionomer Restorations in Adolescents (KETAC)

Not yet recruiting
N/A
80
US
Ketac Universal, Ketac Universal Aplicap Glass Ionomer Restorative (3M ESPE), Ketac Molar Quickset, Ketac Molar Aplicap Glass Ionomer Restorative (3M ESPE)
Louisiana State University Health Sciences Center in New Orleans, 3M ESPE
Dental Caries
11/19
12/19
Gupta, Rajesh
NCT05822635: SpyGlass Surgical Study

Completed
N/A
34
US, RoW
SpyGlass Discover Digital System or SpyGlass DS Direct Visualization System
Boston Scientific Corporation
Pancreatic Diseases, Bile Duct Diseases, Hepatic Disease
12/24
01/25
Nemunaitis, John
NCT03495921: A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

Terminated
3
32
US
Vigil, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy, FANG vaccine, Irinotecan, Camptosar, Camptothecin-11, CPT-11, Temozolomide, Temodar
Gradalis, Inc.
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
01/22
01/22
NCT03073525: A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Completed
2
25
US
Vigil, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy, FANG vaccine, Atezolizumab, TECENTRIQ™, MPDL3280A
Gradalis, Inc., Roche-Genentech
Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
05/19
05/22
FANG Ovarian, NCT01309230: A Trial of FANG™ Vaccine for Participants With Ovarian Cancer

Completed
2
145
US
Vigil™, formerly known as FANG™ vaccine, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy
Gradalis, Inc.
Ovarian Cancer
02/22
02/22
NCT05503797 / 2022-000627-20: A Study to Assess the Efficacy and Safety of FORE8394 in Participants with Cancer Harboring BRAF Alterations

Recruiting
2
250
Europe, Canada, US, RoW
Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R)
Fore Biotherapeutics, Fore Biotherapeutics
Cancer Harboring BRAF Alterations
06/25
08/26
VITAL, NCT02346747: A Trial of Vigil for Participants With Ovarian Cancer

Active, not recruiting
2
92
US
Vigil, bi-shRNAfurin and GMCSF Autologous Tumor Cell Immunotherapy, FANG vaccine, Placebo
Gradalis, Inc.
Ovarian Cancer, Ovarian Neoplasms
12/25
12/25
NCT02736565: Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma

Completed
1
7
US
pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex, Lipoplex
Gradalis, Inc.
Ewing's Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma
08/19
08/20
NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting
1
82
US
VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
VM Oncology, LLC
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
07/26
12/26
NCT03842865: Expanded Access of Vigil in Solid Tumors

Temporarily Not Available
N/A
US
Vigil, Engineered Autologous Tumor Cell Immunotherapy, FANG, IND 14205
Gradalis, Inc.
Solid Tumor, Ewing Sarcoma, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
 
 
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
1200
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/29
06/29
NCT06207032: TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

Recruiting
N/A
500
US
Tempus AI
Cancer
06/29
06/29
Polaris, NCT06018753: Umbrella Study for Analysis of Data Related to Patients with Cancer

Recruiting
N/A
10000
US
Tempus AI
Cancer
09/28
12/28
Edelman, Gerald
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting
1/2
902
US, RoW
DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327
DualityBio Inc., BioNTech SE
Advanced Solid Tumor
06/25
06/25
DB-1310-O-1001, NCT05785741: A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Recruiting
1/2
1000
US, RoW
DB-1310, Trastuzumab, Osimertinib
DualityBio Inc.
Advanced Solid Tumor
08/26
08/26
Schwann, Thomas A
LeAAPS, NCT05478304: Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Recruiting
N/A
6500
Europe, Canada, US
AtriClip LAA Exclusion System
AtriCure, Inc., Population Health Research Institute
Ischemic Stroke, Systemic Embolism
12/31
04/32
Smiddy, Stephanie
BOND3, NCT04452591: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Recruiting
3
190
Japan, US, RoW
Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
12/27
12/29
Gilmore, Jennifer
ECLIPSE, NCT04136002: Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Active, not recruiting
N/A
44467
US
Guardant Health, Inc., Premier Research Group plc
Colorectal Cancer
03/24
12/25
Sholl, Jill
VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2b
102
Europe, Canada, US, RoW
DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
10/24
04/25
Rosen, Ezra
CA209-8H3, NCT03650894: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Active, not recruiting
2
30
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Bicalutamide, Casodex
Providence Health & Services, Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center
Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor
01/25
01/26
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
NCT04092673: Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Recruiting
1/2
30
US
eFT226, Selective translation inhibitor, Sotorasib, Lumarkus, Fulvestrant, Faslodex, Abemaciclib, Verzenia, Trastuzumab, Herceptin
Effector Therapeutics
Solid Tumor, Adult
12/24
03/25
NCT05566574: A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

Recruiting
1/2
84
US
RP-3500, External Beam Radiotherapy (EBRT)
Memorial Sloan Kettering Cancer Center, Repare Therapeutics
Solid Tumor, Metastatic Cancer
09/25
09/25
NCT06065059: Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Terminated
1/2
7
US
TNG348, Olaparib, Lynparza
Tango Therapeutics, Inc.
Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
05/24
05/24
CFT1946-1101, NCT05668585: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Recruiting
1/2
206
Europe, US
CFT1946, Trametinib, Cetuximab
C4 Therapeutics, Inc.
Solid Tumors, Melanoma, NSCLC, CRC, ATC
03/27
04/27
Hamouda, Danae
VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2b
102
Europe, Canada, US, RoW
DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
10/24
04/25
KEYNOTE-D38, NCT05077709: IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC

Active, not recruiting
2
63
Europe, US
IO102-IO103 in combination with pembrolizumab
IO Biotech, Theradex, Almac, NeoGenomics, Merck Sharp & Dohme LLC
Lung Cancer Non Small Cell, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma Bladder
01/24
11/24
NCT05445843: Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Active, not recruiting
2
96
Europe, US, RoW
JDQ443
Novartis Pharmaceuticals
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
11/24
11/27
Mitchell, Shaun
No trials found
Schmelzer, Laura
No trials found
Osten, Dan
No trials found

Download Options